当前位置: X-MOL 学术J. Control. Release › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Progress and prospects of modified starch-based carriers in anticancer drug delivery
Journal of Controlled Release ( IF 10.8 ) Pub Date : 2022-07-28 , DOI: 10.1016/j.jconrel.2022.07.024
Beibei Zhao 1 , Lingjin Li 1 , Xinxin Lv 1 , Jing Du 1 , Zhengbiao Gu 1 , Zhaofeng Li 1 , Li Cheng 1 , Caiming Li 1 , Yan Hong 1
Affiliation  

Recently, the role of starch-based carrier systems in anticancer drug delivery has gained considerable attention. Although there are same anticancer drugs, difference in their formulations account for unique therapeutic effects. However, the exploration on the effect-enhancing of anticancer drugs and their loading system by modified starch from the perspective of carrier regulation is still limited. Moreover, research on the reduced toxicity of the anticancer drugs due to modified starch as the drug carrier mediated by the intestinal microenvironment is lacking, but worth exploring. In this review, we examined the effect of modified starch on the loading and release properties of anticancer drugs, and the effect of resistant starch and its metabolites on intestinal microecology during inflammation. Particularly, the interactions between modified starch and drugs, and the effect of resistant starch on gene expression, protein secretion, and inflammatory factors were discussed. The findings of this review could serve as reference for the development of anticancer drug carriers in the future.



中文翻译:

改性淀粉基载体在抗癌药物递送中的进展与展望

最近,基于淀粉的载体系统在抗癌药物递送中的作用引起了相当大的关注。尽管有相同的抗癌药物,但它们的配方差异导致了独特的治疗效果。然而,从载体调控的角度对变性淀粉增效抗癌药物及其负载系统的探索仍然有限。此外,关于以变性淀粉为药物载体的肠道微环境介导的抗癌药物降低毒性的研究还很缺乏,但值得探索。在这篇综述中,我们研究了变性淀粉对抗癌药物装载和释放特性的影响,以及抗性淀粉及其代谢物对炎症期间肠道微生态的影响。特别,讨论了变性淀粉与药物的相互作用,以及抗性淀粉对基因表达、蛋白质分泌和炎症因子的影响。本综述的研究结果可为未来抗癌药物载体的开发提供参考。

更新日期:2022-07-29
down
wechat
bug